Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Operations

v3.4.0.3
Condensed Consolidated Statement of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenue:    
Medical devices (see Note 2) $ 8,057 $ 985
Engineering services 429 704
Total revenue 8,486 1,689
Cost of revenue:    
Medical devices 6,669 798
Engineering services 319 488
Total cost of revenue 6,988 1,286
Gross profit 1,498 403
Operating expenses:    
Sales and marketing 2,503 1,851
Research and development 2,149 983
General and administrative 3,488 1,662
Total operating expenses 8,140 4,496
Loss from operations (6,642) (4,093)
Other income (expense) net:    
Gain on warrant liability 2,985 0
Interest and other, net 6 (22)
Total other income (expense), net 2,991 (22)
Net loss (3,651) (4,115)
Less: Preferred deemed dividend (3,124) 0
Net loss applicable to common shareholders $ (6,775) $ (4,115)
Basic and diluted net loss per share (In dollars per share) $ (0.44) $ (0.28)
Weighted average number of shares of common stock outstanding, basic and diluted 15,388 14,542